Blog

Coursehelp
June 17, 2018
QUESTION : No Comments

You will develop a research project proposal that will include different parts. This is a research projec

Research Project Proposal

You will develop a research project proposal that will include different parts. This is a research project proposal, not a business plan proposal or business analysis proposal.

You need to think of a research project topic that is interesting to you and related to your field of study. If you are in business or management you can choose a topic related to business or management. For example, there is a new business or new management strategy in the market. You will need to develop a research proposal that you will do a research to find out if the new business strategy or the new management strategy will be good and applicable for your company or not. If you are in information technology you can choose something related to information technology. For example, there is new software or a new hardware in the market. You will need to develop a research proposal that you will do a research to find out if the new software or the new hardware will be good and applicable to your company or not. You will develop a research proposal that will include different parts. The parts are explained below. These parts actually become sections that you need to include and discuss in your research project proposal.

The completed research project proposal will include the following parts/sections.

Abstract: a large paragraph to a one page abstract.

Table of Contents (List of sections/parts of the research project proposal).

-Introduction.

-Review of the Literature.

-Statement of the Problem.

-Purpose of the Study.

-Hypotheses

-Appendices (if there is any appendix necessary such as graph, chart, table, etc.)                                                                                                           –

-Bibliography/References

-Introduction                                                                                                                          

You will introduce the topic or idea that you have for your research proposal. (Maximum 1 page). Example: you are in business and there is a new business strategy or a new management style in the market or you are in technology and a new technology has come to market.

Review of the Literature                                                                                                

you will review a few resources related to the topic of your research. If there is something new in business or technology, you will review and explain a few resources that have talked and written about that. (Estimated: 3-4 pages).

Statement of the Problem                                                                                               

you will explain what the problem is that you want to study.

Example: x business strategy or x management strategy or x technology is good but we don’t have it in our company.(Half page).

Purpose of the Study                                                                                                             

you explain what the purpose of your study is.

Example: the study will try to find out how that x business strategy, or that x management strategy, or that information technology tool, can improve the company or in what ways it can improve the company if you get it for the company. (Half a page).

Hypotheses                                                                                                                                         

You create 3 hypotheses for 3 different ways that your idea can improve your company. (Example: the x business strategy, or the x management strategy, or the x information technology can improve your company at least in 3 ways, each way becomes a hypothesis in your study.

Example:

Hypothesis-1: that x (your idea) will improve the quality of work of company employees. Hypothesis-2: that x (your idea) will improve the production speed of the company. Hypothesis-3: that x will (your idea) will improve ………………………………………………….

Bibliography/References                                                                                                           

You will list a bibliography of resources that you have studied/used for your research proposal. (At least 3 references).

Attention:                                                                                                                                                                           

The research project proposal is estimated at 5 to 7 pages.

Typed, double-spaced, font 12, using APA style.

 

 

Expert Answer

Ans:

Abstract The paper would report the implementation of Kaizen techniques which is the integral part of the lean manufacturing system. The kaizen are prerequisites for any improvement program. Lean manufacturing is a production philosophy is derived from the Toyota Production system (TPS). This concept having goals of reducing eliminating wastes .As waste is potential gain, so eliminating waste is a gain.Kaizen Philosophy focuses on effective work place organization, simplifies work environment, and reduces waste while

READ MORE
Coursehelp
QUESTION : No Comments

Go to the Maple Leaf Foods Company Website (http://www.mapleleaffoods.com/).

Go to the Maple Leaf Foods Company Website (http://www.mapleleaffoods.com/).  Read the latest annual report for Maple Leaf Foods found under the “Investors” tab and then by choosing “Investor Materials”.

Focus on the President’s Message to Shareholders and the Management’s Discussion and Analysis sections of the report. Additionally, briefly review the company Facebook page and YouTube channel and/or other sources to gather information on its marketing strategy

Answer following question and sub parts related to same question, actually break-up hints to answer this question:-

Q: -Maple Leaf Foods – Porters Competitive Analysis

Threat of substitute products

Bargaining power of customers

Bargaining power of suppliers

Threat of Potential Entrants

Also please remember to mention your list of references used.

Expert Answer

The Company’s outcomes are composed into three portions: Meat Products Group Agribusiness Group and Bakery Products Bunch. The Meat Products Group incorporates esteem included arranged meats, lunch units and snacks, and new pork and poultry items sold under driving Canadian brands, for example, Maple Leaf Schneiders and numerous driving local brands
READ MORE
Coursehelp
QUESTION : No Comments

1- Travel and tourism historically have been on the rise. What are some of the factors that have caused t

1- Travel and tourism historically have been on the rise. What are some of the factors that have caused the increase in tourism? How about during the economic downturn?

2-  When the economy is strong people travel. Interestingly enough, the ONLY industry that did not experience a HUGE decrease. Why do you think this industry remains so steady and reliable?

Expert Answer

1. Travel and tourism historically have been on the rise. The factors that have caused the increase in tourism are:-
  • Increase in population after world war 2
READ MORE
Coursehelp
QUESTION : No Comments

In 1982, twenty-three-year-old Diane Elsroth died after taking a Tylenol capsule laced with cyanide

Tylenol: Decades of Dilemmas

The Chicago Capsule Poisonings

In 1982, twenty-three-year-old Diane Elsroth died after taking a Tylenol capsule laced with cyanide. Within five days of her death, seven more people died from taking tainted Tylenol purchased from stores in the Chicago area. At that time, Tylenol generated $525 million per year for McNeil Consumer Products, Inc., a subsidiary of Johnson & Johnson. The capsule form of the pain reliever represented 30 percent of Tylenol sales. McNeil’s marketing studies indicated that consumers found the capsules easy to swallow and believed, without substantiation, that Tylenol in capsule form worked faster than Tylenol tablets. The capsule’s design, however, meant they could be taken apart, tainted, and then restored to the packaging without evidence of tampering. After the Chicago poisonings, which were never solved, McNeil and Johnson & Johnson executives were told at a meeting that processes for sealing the capsules had been greatly improved, but no one could give the assurance that they were tamperproof. The executives realized that abandoning the capsule would give their competitors, Bristol-Myers (Excedrin) and American Home Products (Anacin), a market advantage, plus the cost would be $150 million just for 1982. Jim Burke, CEO of Johnson & Johnson, told the others that without a tamperproof package for the capsules, they would risk the survival of not only Tylenol but also Johnson & Johnson. The executives decided to abandon the capsule. Frank Young, a Food and Drug Administration (FDA) commissioner, stated at the time, “This is a matter of Johnson & Johnson’s own business judgment, and represents a responsible action under tough circumstances.” Johnson & Johnson quickly developed “caplets”—tablets in the shape of a capsule then offered consumers a coupon for a bottle of the new caplets if they turned in their capsules. Within five days of the announcement of the capsule recall and caplets offer, 200,000 consumers had responded. Johnson & Johnson had eliminated a key product in its line—one that customers clearly preferred—in the interest of safety. Otto Lerbinger of Boston University’s College of Communication cited Johnson & Johnson as a “model of corporate social responsibility for its actions.” President Ronald Reagan, addressing a group of business executives, said, “Jim Burke, of Johnson & Johnson, you have our deepest admiration. In recent days you have lived up to the very highest ideals of corporate responsibility and grace under pressure.” Within one year of the Tylenol poisonings, Johnson & Johnson regained its 40 percent market share for Tylenol. While many attribute the regain of market share to tamperproof packaging, the other companies had moved to that form as well. However, it is interesting to note that McNeil was able to have its new product and packaging on the shelves within weeks of the fatal incidents. There had been some preparation for the change prior to the fatalities, but the tragedy was the motivation for the change to safer packaging and product forms. McNeil has continued to enjoy the goodwill from its rapid response to the poisonings as well as its willingness to take the financial hit for what experts believed was a very small risk that there was more cyanide-laced Tylenol out on the shelves. In fact, the recall was so indelibly etched in the public’s mind and in the minds of those in the field of business ethics that McNeil, Johnson & Johnson, and Tylenol itself were often given free passes on conduct that did pose safety risks to customers. As new issues with Tylenol have developed, McNeil seems to be given the benefit of the doubt because of the goodwill and reputational capital it purchased with the capsule recalls.

Tylenol and Liver Damage

On December 21, 1994, the Journal of the American Medical Association published the results of a five-and-one-half-year study showing that moderate overdoses of acetaminophen (known most widely by the brand name Tylenol) led to liver damage in ten patients. The damage occurred even in patients who did not drink and was most pronounced in those who did drink or had not been eating. Further, the study by Dr. David Whitcomb at the University of Pittsburgh Medical School found that taking one pill of acetaminophen per day for a year may double the risk of kidney failure. 64 By 2001, there were 450 deaths due to liver failure from Tylenol overdoses. At that time, the American Association of Poison Control Centers called acetaminophen poisonings the most common of all reported poisonings. 65 The number of pediatric poisonings from overdoses of acetaminophen has more than tripled since 1996. As a result, the FDA adjusted the adult and pediatric doses that were acceptable in 2009. However, adult deaths from overexposure are more likely to be the result of suicidal ingestion. Tylenol is a stunning source of revenue for McNeil and Johnson & Johnson, with revenue totals growing at double-digit rates as Tylenol expands market presence into 5,000 convenience stores with new and smaller packaging of its product and its new formulas such as Tylenol PM. Tylenol users who claimed they were victims of overdose and liver damage and the lack of effective warnings have not been successful against Johnson & Johnson. McNeil has modified the recommended dosages, the ad claims, and language on its labels. The product labels before current modification read, “Gentle on an infant’s stomach,” and Tylenol’s ad slogan was “Nothing’s safer.” That language has been removed and McNeil added to its infant Tylenol label: “Taking more than the recommended dose . . . could cause serious health risks” because of liver damage in children. McNeil also responded to data that showed patients who combine Tylenol with alcohol have produced 200 cases of liver damage in the past twenty years, with fatality in 20 percent of those cases. The level of alcohol use by patients among these cases was multiple drinks every day. McNeil modified its labels to include bold warnings about alcohol use and the dangers of combining Tylenol with any drinking. Despite the extensive coverage of the issues surrounding Infant Tylenol, Tylenol overdoses, and issues with liver damage from combining alcohol and Tylenol, the company did not experience any loss of market share or even extensive negative media coverage. The goodwill from Tylenol’s earlier recall appeared to see it through these crises. However, others issues were emerging.

The Tylenol Quality Control Program

In May 2010, the FDA was considering bringing criminal charges against McNeil for a pattern of violations in its quality control in the production of children’s Tylenol. The charges would spring from the April 30, 2010, recall by McNeil of 136 million bottles of liquid pediatric Tylenol, Motrin, Benadryl, and Zyrtec because the medicines contained too much metal debris or too much of the necessary active ingredient in these over-the-counter drugs. Because of the presence of metal debris, the medicine batches failed FDA testing. However, prior to the FDA testing and the recall, there was evidence that McNeil was aware of the developing problem but took no public action. A purchase order that the company turned over to congressional investigators indicated that McNeil had hired a contractor in 2009 to visit 5,000 stores and buy Motrin from the shelves. The contractor’s PowerPoint materials instructed employees to act like any other customer and make “no mention of this being a recall when making a purchase.” McNeil indicated to congressional investigators that “The Motrin Purchase Project” was created by a McNeil subcontractor without its knowledge and approval. McNeil said it notified the FDA about two Motrin lots that did not dissolve properly and that it was removing the Motrin from the shelves. The evidence submitted for the hearings showed that McNeil had received forty-six complaints from consumers about black particles in Tylenol and other McNeil products. However, McNeil did not notify the FDA nor did it recall the medicines. The inaction in the face of customer harm represented the straw that broke the FDA’s back of tolerance because the company, at that point, was finishing two years of an ongoing tussle with regulators over quality control. At one plant that manufactured Children’s Tylenol, seven batches of product were released after testing revealed problems in three batches. The agency’s frustration in dealing with the plants and managers for inaction and ongoing violations led to the review of the company for possible criminal charges. The surreptitious removal of Motrin from retail stores because McNeil had discovered quality control problems with that product was referred to by the FDA as, in effect, an unannounced or “phantom” recall. Also in 2008, McNeil failed to notify the FDA that it had received complaints from customers about a moldy smell in some of the products made in its Puerto Rico production facilities and, at the same time, failed to disclose complaints from customers about stomach problems experienced after they had used the “moldy” products. McNeil tested the products and found no problems, but the complaints continued through 2009. Further testing showed that the medicine had been contaminated by a chemical used in the plant for the treatment of wooden shipping pallets. One member of Congress noted that the recall on the “smell” issue took one year and that it should have taken 3 days. At another plant, the FDA found that the company “knowingly” used an ingredient that was tainted with Burkholderia cepacia, a bacteria that most healthy people can handle but that can cause serious infections in those with chronic illnesses such as cystic fibrosis. Another member of Congress said of the congressional inquiry, “We are not getting the kind of information and cooperation from Johnson that I would like.” As consumers purchased generic brands to substitute for the recalled Tylenol products, quality problems emerged in those medicines as well. In addition to the criminal charges, the FDA is studying the production quality issue from an industry perspective and is considering revamping the production and testing requirements for all over-the-counter drug manufacturers. The agency released the letters that it sent to forty-three drug factories for their failure to correct “shoddy manufacturing practices that may have exposed patients to health risks.” The letters indicated that FDA inspectors had found insects in equipment and ingredients, improper testing, failure to conduct required tests, and disregard for customer complaints. More than half of the plants inspected had violations, even if those violations did not rise to the level of receiving the agency’s letter warning. Discussion Questions

Questions:

4. What can you conclude from the quick development and appearance of the new product line?

5. Following the 2010 misstep, Tylenol’s competitors have been sending out free samples and coupons to Tylenol customers who participated in the Tylenol recall as a way of getting them to try their products. Why would such a campaign at this time result in more sales of their products? What is different about this issue versus the cyanide poisonings? Make a list of the distinctions between the two series of events, including descriptions of company and customer responses.

6. General Robert Wood Johnson, the CEO of Johnson & Johnson from 1932 to 1963, wrote a credo for his company that states the company’s first responsibility is to the people who use its products and services, the second responsibility is to its employees, the third to the community and its environment, and the fourth to the stockholders. Johnson and his successors have believed that if the credo’s first three responsibilities are met, the stock- holders will be well served. Does Johnson & Johnson follow its credo?

7. Why did the company drag its heels on the later recalls? What was the purpose of the phantom contractor and the resulting unannounced recall?

8. Did the company ride the coattails of its recall recognition from the 1987 poisonings for too long? Was there hubris involved?

9. A lawyer who represents clients suing McNeil offered the following observations: “It [McNeil] markets itself as a company that takes children’s safety very seriously and that’s why they can charge a premium price for the Tylenol. People are willing to pay a premium price because of a reputation for safety. Now they’re being deceived.” Another lawyer who represents companies before the FDA added, “The value of the brand is such that that’s got to be the first thought.” What thoughts are the lawyers offering on cost analysis in ethical issues through their experiences and observations?

Expert Answer

4. What can you conclude from the quick development and appearance of the new product line?

The developing of new product line is not only what is expected but is more than the usual expectation of the customer. When a defect or problem is identified, any company’s usual response would be to replace the product with a new batch of the same product. However, in case of Tylenol, J&J not just replaced the product, but also did

READ MORE
Coursehelp
QUESTION : No Comments

From the first e-Activity, examine at least three different types of lean waste that can be found at NIKE

From the first e-Activity, examine at least three different types of lean waste that can be found at NIKE. Suggest the lean strategies to confront them. there are 7 different types of Lean waste.

Expert Answer

Ans:

Nike’s assembling impression is gigantic. As of this composition, they have producing contracts with more than 785 manufacturing plants, crosswise over India, Vietnam, Philippines, and South America. Also throughout the years Nike has been censured for its absence of oversight of its makers. At first they drew nearer the issue as an approach to oversee notoriety.

READ MORE
Coursehelp
QUESTION : No Comments

[Solved] From the first e-Activity, examine at least three different types of lean waste that can be found at NIKE

From the first e-Activity, examine at least three different types of lean waste that can be found at NIKE. Suggest the lean strategies to confront them. there are 7 different types of Lean waste.

Expert Answer

Ans:

Nike’s assembling impression is gigantic. As of this composition, they have producing contracts with more than 785 manufacturing plants, crosswise over India, Vietnam, Philippines, and South America. Also throughout the years Nike has been censured for its absence of oversight of its makers. At first they drew nearer the issue as an approach to oversee notoriety.

READ MORE
Coursehelp
QUESTION : No Comments

Paul Wolfowitz was the head of the World Bank from June 1, 2005 until May 17, 2007. Mr. Wolfowitz was

Paul Wolfowitz and the World Bank
Paul Wolfowitz was the head of the World Bank from June 1, 2005 until May 17, 2007. Mr. Wolfowitz was romantically involved with an executive at the bank, Shaza Riza. Mr. Wolfowitz went to the board with an ethics question about their relationship and her continuing employment. The bank board advised that Ms. Riza be relocated to a position beyond Mr. Wolfowitz’s influence because of their relationship and also because their relationship would preclude her being promoted at the bank. On August 11, 2005, Mr. Wolfowitz wrote a memo to Xavier Coll, the bank’s vice president of human resources, and suggested the following:
I now direct you to agree to a proposal which includes the following terms and conditions:
The terms and conditions included her future at the bank when Mr. Wolfowitz was no longer heading it as well as an obligation to find her other employment. Ms. Riza now earns $193,590 per year at a nonprofit organization, following a stint at the State Department at World Bank expense. She earned $132,000 at the World Bank (a salary that was tax-free because of diplomatic status).
In response to the questions raised about his relationship and the memo, Mr. Wolfowitz posted the following explanation on the World Bank website:
Let me just say a few words about the issue on everyone’s mind. Two years ago, when I came to the Bank, I raised the issue of a potential conflict of interest and asked to be recused from the matter. I took the issue to the Ethics Committee and after extensive discussions with the Chairman, the Committee’s advice was to promote and relocate Ms. Shaza Riza.
I made a good faith effort to implement my understanding of that advice, and it was done in order to take responsibility for settling an issue that I believed had potential to harm the institution. In hindsight, I wish I had trusted my original instincts and kept myself out of the negotiations. I made a mistake, for which I am sorry.
Not only was this a painful personal dilemma, but I also had to deal with it when I was new to this institution and I was trying to navigate in un-charted waters. The situation was unprecedented and exceptional. This was an involuntary reassignment and I believed there was a legal risk if this was not resolved by mutual agreement. I take full responsibility for the details. I did not attempt to hide my actions nor make anyone else responsible.
I proposed to the Board that they establish some mechanism to judge whether the agreement reached was a reasonable outcome. I will accept any remedies they propose.
In the larger scheme of things, we have much more important work to focus on. For those people who disagree with the things that they associate me with in my previous job, I’m not in my previous job. I’m not working for the U.S. government, I’m working for this institution and its 185 shareholders. I believe deeply in the mission of the institution and have a passion for it. I think the challenge of reducing poverty is of enormous importance.

Question:
1. What ethical issues do you see?
2. Did Mr. Wolfowitz act properly? Do you see any rationalizations?
3. What should the board have done?

Expert Answer

1. There are multiple ethical issues.

a) It is unclear how discussions between the Ethics Committee and Mr Wolfowitz can lead to a promotion of Ms. Shaza Riza

b) Mr. Wolfowitz is in no position to send the memo to the head of human resources which had terms and conditions that were clearly unfair

READ MORE
Coursehelp
QUESTION : No Comments

[Solved] Paul Wolfowitz was the head of the World Bank from June 1, 2005 until May 17, 2007. Mr. Wolfowitz was

Paul Wolfowitz and the World Bank
Paul Wolfowitz was the head of the World Bank from June 1, 2005 until May 17, 2007. Mr. Wolfowitz was romantically involved with an executive at the bank, Shaza Riza. Mr. Wolfowitz went to the board with an ethics question about their relationship and her continuing employment. The bank board advised that Ms. Riza be relocated to a position beyond Mr. Wolfowitz’s influence because of their relationship and also because their relationship would preclude her being promoted at the bank. On August 11, 2005, Mr. Wolfowitz wrote a memo to Xavier Coll, the bank’s vice president of human resources, and suggested the following:
I now direct you to agree to a proposal which includes the following terms and conditions:
The terms and conditions included her future at the bank when Mr. Wolfowitz was no longer heading it as well as an obligation to find her other employment. Ms. Riza now earns $193,590 per year at a nonprofit organization, following a stint at the State Department at World Bank expense. She earned $132,000 at the World Bank (a salary that was tax-free because of diplomatic status).
In response to the questions raised about his relationship and the memo, Mr. Wolfowitz posted the following explanation on the World Bank website:
Let me just say a few words about the issue on everyone’s mind. Two years ago, when I came to the Bank, I raised the issue of a potential conflict of interest and asked to be recused from the matter. I took the issue to the Ethics Committee and after extensive discussions with the Chairman, the Committee’s advice was to promote and relocate Ms. Shaza Riza.
I made a good faith effort to implement my understanding of that advice, and it was done in order to take responsibility for settling an issue that I believed had potential to harm the institution. In hindsight, I wish I had trusted my original instincts and kept myself out of the negotiations. I made a mistake, for which I am sorry.
Not only was this a painful personal dilemma, but I also had to deal with it when I was new to this institution and I was trying to navigate in un-charted waters. The situation was unprecedented and exceptional. This was an involuntary reassignment and I believed there was a legal risk if this was not resolved by mutual agreement. I take full responsibility for the details. I did not attempt to hide my actions nor make anyone else responsible.
I proposed to the Board that they establish some mechanism to judge whether the agreement reached was a reasonable outcome. I will accept any remedies they propose.
In the larger scheme of things, we have much more important work to focus on. For those people who disagree with the things that they associate me with in my previous job, I’m not in my previous job. I’m not working for the U.S. government, I’m working for this institution and its 185 shareholders. I believe deeply in the mission of the institution and have a passion for it. I think the challenge of reducing poverty is of enormous importance.

Question:
1. What ethical issues do you see?
2. Did Mr. Wolfowitz act properly? Do you see any rationalizations?
3. What should the board have done?

Expert Answer

1. There are multiple ethical issues.

a) It is unclear how discussions between the Ethics Committee and Mr Wolfowitz can lead to a promotion of Ms. Shaza Riza

b) Mr. Wolfowitz is in no position to send the memo to the head of human resources which had terms and conditions that were clearly unfair

READ MORE
Coursehelp
QUESTION : No Comments

1 – Is inventory an asset or a liability? How do we determine if it is an asset or a liability? Please provide

1 – Is inventory an asset or a liability? How do we determine if it is an asset or a liability? Please provide specific examples.

2- As a flow-over from the inventory management discussion thread, How does an ABC approach improve inventory management?

Expert Answer

Inventory is the collection of unsold products waiting to be sold. Inventory is listed as a current asset on a company’s balance sheet.

Further we can say, Inventory is commonly thought of as the finished goods a company accumulates before selling them to end users.

READ MORE
Coursehelp
QUESTION : No Comments

[Solved] 1 – Is inventory an asset or a liability? How do we determine if it is an asset or a liability? Please provide

1 – Is inventory an asset or a liability? How do we determine if it is an asset or a liability? Please provide specific examples.

2- As a flow-over from the inventory management discussion thread, How does an ABC approach improve inventory management?

Expert Answer

Inventory is the collection of unsold products waiting to be sold. Inventory is listed as a current asset on a company’s balance sheet.

Further we can say, Inventory is commonly thought of as the finished goods a company accumulates before selling them to end users.

READ MORE